Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
PMDA is regarded among the most stringent regulatory bodies globally
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Subscribe To Our Newsletter & Stay Updated
